ZICHEM PHARMA
ActiveSummary
ZICHEM PHARMA has been active since 1987 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €538k and a net result of €40k. Equity is growing by ~11.7% per year across the filed fiscal years. Its solvency ranks better than 93% of 10407 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Checked score
Score 2025
78
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability77▲+3
Solvency100=
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40k at 30 days acceptable
Liquidity ample (current ratio 6.92 against 6.04 in 2024; short-term debt: 13.5% and cash: 0.7% of total assets), and 13.5% of the assets are financed with debt.
Credit check for your own amount and term
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
86.5%
Return on assets
6.5%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 12-05-2026, 80 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
80 d early
2024
45 d early
2023
49 d early
2022
52 d early
2021
54 d early
2020
47 d early
2019
17 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€538k▲ 8.1%
2024 · €498k
2018: €265k
2019: €279k
2020: €318k
2021: €360k
2022: €419k
2023: €474k
2024: €498k
2018 → 2025
Total assets
€622k▲ 5.9%
2024 · €588k
2018: €333k
2019: €327k
2020: €379k
2021: €418k
2022: €488k
2023: €608k
2024: €588k
2018 → 2025
Net result
€40k▲ 67.9%
2024 · €24k
2018: €30k
2019: €14k
2020: €39k
2021: €42k
2022: €59k
2023: €55k
2024: €24k
2018 → 2025
Working capital
€499k▲ 10.3%
2024 · €452k
2018: €203k
2019: €223k
2020: €267k
2021: €309k
2022: €369k
2023: €427k
2024: €452k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€360k-€419k▲ 16.4%€474k▲ 13.1%€498k▲ 5.1%€538k▲ 8.1%
Operating result€53k-€74k▲ 39.5%€62k▼ 17.1%€19k▼ 68.9%€44k▲ 128%
Net result€42k-€59k▲ 40.5%€55k▼ 6.5%€24k▼ 56.5%€40k▲ 67.9%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 128% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €622k
Fixed assets
€40k ▼ 13.8%
Current assets
€583k ▲ 7.6%
Equity and liabilities €622k
Equity
€538k ▲ 8.1%
Debt
€84k ▼ 6.2%
Debt's share of the balance-sheet total falls from 15.3% to 13.5%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€50k▲
2024 · €29k
Cash flow
€47k▲
2024 · €33k
Current ratio
6.92▲
2024 · 6.04
Quick ratio
5.79▲
2024 · 5.09
Debt to equity
0.16▼
2024 · 0.18
ROE
7.5%▲
2024 · 4.8%
ROA
6.5%▲
2024 · 4.1%
Interest coverage
105.02▲
2024 · 68.01
Debt ≤ 1 year
€84k▼
2024 · €90k
Income taxes
€13k▲
2024 · €8k
Staff costs
€360▲
2024 · €101
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 42 lines
Balance sheet
Code20242025
Assets
Total assets20/58€588k€622k▲
Fixed assets21/28€46k€40k▼
Intangible fixed assets21€0€0=
Tangible fixed assets22/27€46k€39k▼
Land and buildings22€32k€30k▼
Plant, machinery and equipment23€8k€5k▼
Furniture and vehicles24€6k€4k▼
Financial fixed assets28€245€245=
Current assets29/58€542k€583k▲
Stocks and contracts in progress3€85k€96k▲
Stocks30/36€85k€96k▲
Amounts receivable within one year40/41€451k€483k▲
Trade receivables40€109k€113k▲
Other amounts receivable41€342k€370k▲
Cash at bank and in hand54/58€6k€4k▼
Equity and liabilities
Total equity and liabilities10/49€588k€622k▲
Equity10/15€498k€538k▲
Contributions10/11€7k€7k=
Reserves13€491k€531k▲
Distributable reserves133€491k€531k▲
Amounts payable17/49€90k€84k▼
Amounts payable within one year42/48€90k€84k▼
Trade debts44€86k€81k▼
Suppliers440/4€86k€81k▼
Taxes, remuneration and social security45€3k€3k▲
Taxes450/3€3k€3k▲
Income statement
Code20242025
Remuneration, social security and pensions62€101€360▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€9k€6k▼
Other operating charges640/8€2k€2k▲
Gross operating margin9900€30k€52k▲
Operating profit (loss)9901€19k€44k▲
Financial income75/76B€13k€10k▼
Recurring financial income75€13k€10k▼
Financial charges65/66B€421€478▲
Recurring financial charges65€421€478▲
Profit (loss) for the period before taxes9903€32k€54k▲
Income taxes67/77€8k€13k▲
Profit (loss) for the period9904€24k€40k▲
Profit (loss) for the period to be appropriated9905€24k€40k▲
Appropriation of the result
Profit (loss) to be appropriated9906€24k€40k▲
Transfer to equity691/2€24k€40k▲
To other reserves6921€24k€40k▲
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
12-08
State Gazette act
Resignation: ALEXO (director)Permanent representatives: Olivier Delaere, Koen Straetmans and Tom Goderis · Appointment: KST Pharma (director) · Reappointment: SODIAP (managing director)8 facts ▸
State Gazette act
Resignation: ALEXO (director)
Permanent representatives: Olivier Delaere, Koen Straetmans and Tom Goderis · Appointment: KST Pharma (director) · Reappointment: SODIAP (managing director)8 facts ▸
- General meeting, 19/05/2026
- Director resignation, ALEXO (director)
- Permanent representative, Olivier Delaere
- Director appointment, KST Pharma (director)
- Permanent representative, Koen Straetmans
- Board meeting, 19/05/2026
- Director reappointment, SODIAP (managing director)
- Permanent representative, Tom Goderis
12-05
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Equity above €500kEq €538k ▲8.1%
8 profitable years in a row build equity to €538k.
16-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
12-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
09-06
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Highest result since 2018net €59k ▲40.5%
Operating result €74k, net result €59k, both a record.
07-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
14-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
14-07
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
31-12
Financial
Weakest financial yearnet €14k ▼51.7%
Net result drops to €14k, the lowest in the series; recovery starts the following year.
09-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
28-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
10-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 7 acts read
About the unread acts
Of the 7 Belgian State Gazette acts we know for this company, 1 has been read. The other 6 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 directors, last change in 2026
KST Pharma
CurrentDirector · since 19-05-2026 · Legal entity · perm. rep.: Koen Straetmans
SODIAP
CurrentManaging director · since 19-05-2026 · Legal entity · perm. rep.: Tom Goderis
19-05-2026
KST Pharma: Appointed as Director
19-05-2026
SODIAP: Mandate renewed as Managing director
19-05-2026
Alexo: Resigned as Director
Not every act has been read: a resignation may be missing here
6 of this company's 7 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Scherpenheuvel-Zichem · 1 establishment unit since 1987
Ground area
208 m²
Building footprint
208 m²
Volume, LiDAR
1,591 m³
Parcel 24129E0103/00R000, Flanders · tallest building 11.8 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
Zichem Pharma
since 19872.030.000.360
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24129E0103/00R000 | Flanders | 208 m² | 1 · 208 m² | 11.8 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
1 siteScherpenheuvel-Zichem2.030.000.360
Similar companies · same sector, comparable size
Pharmacie BASTIN - JEANJOT
BE 0447.021.134
Vaux-sur-Sûre · Eq €538,548
Ma Ressource Santé
BE 0844.355.997
Sint-Lambrechts-Woluwe · Eq €538,664
PHARMACIE DE MARIE
BE 0676.494.727
Binche · Eq €537,474
HALLEPHAR
BE 0426.472.178
Zoersel · Eq €537,464
PHARMACIE DUBOIS NORTIER
BE 0463.186.381
Verviers · Eq €539,074
Of 5,220 companies in sector 47730 we hold annual accounts for 3,861. 3,339 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded21-08-1987
Fiscal year end31-12
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesBelgian Official Gazette · 1 actNational Bank · 39 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.